Cardiology

Lege Artis Medicinae

NOVEMBER 23, 2023

[Women and cardiovascular diseases]

BENCZÚR Béla

[There are major differences between women and men in risk factor profiles, social and environmental factors, clinical features, recognition and treatment of cardiovascular diseases. According to the recent statistical data, it is no mere chance that more females than males die in these conditions. Beyond traditional risk factors, women have unique special ones, which significantly influence the development of their future cardiovascular diseases. This review provides a brief summary about specific cardiovascular diseases like atherosclerosis, atrial fibrillation, heart failure and myocardial infarction with their sex- and gender-related features. If healthcare providers paid more attention to this body of knowledge, it should improve recogni­tion, treatment, and outcomes of women’s cardiovascular conditions. ]

HUN 2023;33(10-11)

Lege Artis Medicinae

NOVEMBER 23, 2023

[Statin monotherapy or immediate statin and ezetimibe combination? – analysis of Polish ACS-register]

VARJAS Norbert

[ ]

HUN 2023;33(10-11)

Hypertension and nephrology

OCTOBER 30, 2023

[Chronic kidney disease and venous thromboembolic events]

VÁRADY Tímea, MÁCSAI Emília, SZLOVÁK Edina, DOLGOS Szilveszter

[Our aim is to analyse venous thromboembolic events regarding chronic kidney disease. Based upon epidemiologic data, both thromboembolic and haemorrhagic events are more frequent among patients with chronic kidney disease. Changes in levels of coagulant factors, thrombocyte and endothel disfunction, uremic toxins and dialysis related issues share role in pathogenesis. Guidelines lack of adequate information regarding this specific patient group. Therapeutic shift can be observed from vitamin K antagontists toward direct oral anticoagulants, not only in general population but also in CKD patients, with special interest in apixaban. Another therapeutic trend is change from unfractioned heparin to low molecular weigh heparins with anti Xa level monitoring among CKD population. Special attention is needed for thrombotic events related to eritropoietin therapy and hemodialysis access.]

HUN 2023;27(05)

Lege Artis Medicinae

SEPTEMBER 30, 2023

[V. Hypertonia Days Szekszárd]

[ ]

HUN 2023;33(8-9)

Lege Artis Medicinae

SEPTEMBER 30, 2023

[Difficulties in recognising and treatment of lower extremity arterial disease in the elderly]

FARKAS Katalin

[ 

Cardiovascular disease is the most important cause of morbidity and mortality in elderly individuals worldwide. Lower extremity arterial disease is a diffuse degenerative process by atherosclerosis of the concerning arteries that can narrow or completely block the lumen of the arteries. One of the most important risk factors is the age, thus the occurrence of lower extremity arterial dis­ease increases significantly with it exceeding 20% over the age of 70. The incidence of lower extremity arterial disease is mounting worldwide and one of the reasons for is the increase in the average age of the popula­tion. Recognition and also treatment of the disease show elderly characteristics, the knowledge of which is important in caring for increasing population of elderly patients with lower extremity arterial disease. Early detection and corresponding preventive treatment have a significant role also in this population. The wider range of intervention options can also provide an opportunity for elderly high-risk patients to avoid amputa­tion and get a better quality of life.]

HUN 2023;33(8-9)

Hypertension and nephrology

SEPTEMBER 13, 2023

[Lipid-lowering therapy in hypertension: what, how much and when?]

HARANGI Mariann, KOVÁCS Beáta

[Hypertension and dyslipidemia are two main risk factors for cardiovascular diseases. Hyperlipidemia and hypertension co-exist in a large proportion of patients. Furthermore, people dealing with hyperlipidemia and hypertension are at a higher risk of developing cardiovascular diseases than those who suffer from hyperlipidemia or hypertension. Therefore, an essential aspect of hypertension therapy is the management of hyperlipidemia as it can prevent the progression of atherosclerosis and related macrovascular events such as myocardial infarction and stroke. Previous studies have demonstrated that 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor statins were associated with an unexpected reduction in blood pressure in hypertensive patients. Fibrates and omega-3 fatty acids may also improve the efficacy of antihypertensive treatment. These pharmacological approaches have a favorable effect on both lipids and blood pressure thresholds. These treatments hold great promise in preventing cardiovascular complications in this unique population.]

HUN 2023;27(04)